Executive summary
US Patent 7,169,381 claims dry, admixture-ready compositions that, when dissolved to 1 liter, yield 300–700 mOsmol/kg solutions and that combine polyethylene glycol (PEG) with ascorbic acid (and/or salts, including sodium ascorbate) and specified inorganic electrolytes (especially alkali/alkaline earth sulphates, with optional NaCl/KCl/NaHCO₃). Dependent claims narrow by PEG molecular weight (2000–4500 Da; exemplified 3350 or 4000 Da), component loadings (PEG 90–150 g; sulphate 3–9 g; ascorbate/ascorbic mix 5–10 g), ascorbate/ascorbic acid weight ratios (broad 1:9 to 9:1; tighter 4:6–6:4), and form factors including sachets, kits with separated portions, and the resulting colon cleansing preparation.
The claim set is largely “formulation-centric” (composition + osmolarity + ingredient ranges) with limited method coverage. The patent estate is likely vulnerable to design-around via (i) shifting away from the claimed osmolarity window, (ii) using alternative osmotic agents/electrolyte systems, (iii) changing the PEG type/loadings outside narrower dependent ranges, (iv) avoiding the claimed electrolyte class (alkali/alkaline earth sulphates), or (v) changing packaging architecture. Enforcement and validity risk will hinge on how precisely an accused product maps to the liter-based quantitative ranges and the measured osmolarity of the reconstituted solution.
What is US Patent 7,169,381 and what does it claim for colon cleansing?
Direct answer: US 7,169,381 claims dry colon cleansing compositions that, when reconstituted in water to make 1 liter, have osmolarity 300–700 mOsmol/kg and contain PEG + ascorbic acid/ascorbate + specified electrolytes, with downstream product claims for the aqueous preparation, sachet, and two-portion kit packaging.
Claim architecture and effective scope
The independent claim (Claim 1) sets three core constraints and then dependent claims narrow:
-
Reconstitution/Osmolarity constraint
- “Per liter of aqueous solution to be made” and the solution has 300 to 700 mOsmol/kg.
-
PEG-osmotic component
- 80 to 350 g PEG per liter.
-
Ascorbic acid system
- 3 to 20 g of “a mixture of ascorbic acid and one or more salts of ascorbic acid.”
-
Electrolyte system
- 1 to 15 g of alkali metal or alkaline earth metal sulphate (or mixture).
- Optional electrolytes: NaCl, KCl, NaHCO₃.
Then dependent claims refine:
- Osmolarity targets (≥330; ≤550)
- PEG molecular weight (≥2000; ≤4500; specific 3350 or 4000)
- Component loading tighter bands (PEG ≥90 and ≤150; sulphate ≥3 and ≤9; ascorbic mix ≥5 and ≤10)
- Specific cations (Mg, Na) and specific salts (NaCl; KCl)
- Ascorbic acid/salt ratio (1:9 to 9:1)
- Specific salt identity (sodium ascorbate)
- Add-ons: flavoring and specific sweeteners (aspartame, acesulfame K, saccharine, citric acid)
- Coated ascorbate/ascorbic
- Product forms: aqueous preparation, sachet, and kit with separated portions (ascorbic system in a first portion; other components in a second).
Key independent vs dependent coverage map
| Claim group |
What it covers |
Main legal/technical hook |
| Claim 1 (independent) |
Dry admixture composition with PEG + ascorbic system + sulphates; solution osmolarity 300–700 mOsm/kg; optional NaCl/KCl/NaHCO₃ |
Composition + reconstitution osmolarity ranges |
| Claims 28–30 |
“Colon cleansing preparation” and packaging forms (sachet/kit) based on Claim 1 composition |
Product form derived from the composition |
| Claim 31 (independent) |
Same concept but with a different PEG and electrolyte detail: PEG 30–350 g, ascorbic 3–20 g, optional electrolytes include sulphates + NaCl/KCl/NaHCO₃ (sulphate not necessarily mandatory in claim 31 text as written) |
Different claim boundary on sulphate requirement and formulation amounts |
| Claims 38–40 |
Product forms (aqueous, sachet, kit) based on Claim 31 composition |
Product form derived from the composition |
What is the full claim scope by ingredient and osmolarity in US 7,169,381?
Direct answer: The narrowest technical consensus across the independent claims is: reconstitute to 1 liter and hit 300–700 mOsmol/kg while including PEG and ascorbic acid/ascorbate plus electrolytes, with sulphates prominently required in Claim 1.
Osmolarity: the measurable boundary condition
| Osmolarity limitation |
Claim(s) |
Practical implication for infringement/validity |
| 300–700 mOsmol/kg |
Claim 1, Claim 31 |
Primary infringement boundary; measured in the accused product reconstitution conditions |
| ≥330 mOsmol/kg |
Claim 2 |
Moves boundary upward; may exclude lower-osmolarity formulations |
| ≤550 mOsmol/kg |
Claim 3 |
Moves boundary downward; may exclude higher-osmolarity formulations |
PEG: quantity and molecular weight
| PEG parameter |
Claim(s) |
Range/value |
| PEG amount per liter |
Claim 1 |
80–350 g |
| PEG amount per liter |
Claim 31 |
30–350 g |
| PEG MW minimum |
Claim 4 |
≥2000 Da |
| PEG MW maximum |
Claim 5 |
≤4500 Da |
| Exemplified PEG MW |
Claim 6 |
3350 or 4000 Da |
| Tight PEG loading |
Claim 7 and 8 |
≥90 g and ≤150 g |
| Specific PEG loading |
Claim 9 |
100 g |
Ascorbic acid/ascorbate system: identity and ratio
| Ascorbic parameter |
Claim(s) |
Range/value |
| Total ascorbic acid + salt amount |
Claim 1 |
3–20 g |
| Total ascorbic acid + salt amount |
Claim 31 |
3–20 g |
| Ascorbic/salt ratio |
Claim 21; Claim 34; Claim 35 |
broad 1:9 to 9:1; narrower 4:6 to 6:4 |
| Minimum ascorbic mixture |
Claim 19 |
≥5 g |
| Maximum ascorbic mixture |
Claim 20 |
≤10 g |
| Salt identity |
Claim 22, 32, 33 |
sodium ascorbate |
| Coated ascorbic/salt |
Claim 27 |
coated ascorbic acid and/or salt |
Sulphate electrolyte: quantity and identity levers
| Sulphate parameter |
Claim(s) |
Range/value |
| Sulphate amount per liter |
Claim 1 |
1–15 g |
| Tight sulphate loading |
Claim 10 and 11 |
≥3 g and ≤9 g |
| Specific sulphate amount |
Claim 12 |
7.5 g |
| Sulphate cation selection |
Claim 13 |
magnesium |
| Sulphate cation selection |
Claim 14 |
sodium |
| Explicit sulphate salt |
Claim 37 |
sodium sulphate |
Optional electrolytes and sweetener/flavor add-ons
| Optional component |
Claim(s) |
What it narrows |
| Sodium chloride |
Claim 15, 16 |
inclusion and ≥2 g/L |
| Potassium chloride |
Claim 17, 18 |
inclusion and ≥0.5 g/L |
| Sodium hydrogen carbonate |
Claim 31 |
optional; presence in the optional list |
| Flavoring |
Claim 23 |
flavoring presence |
| Lemon flavor |
Claim 24 |
lemon flavoring presence |
| Sweetener class |
Claim 25 |
sweetener not “metabolic substrate for bacteria in the gut” |
| Specific sweeteners |
Claim 26 and 36 |
aspartame, acesulfame K, saccharine, citric acid |
Packaging and kit architecture
| Product form |
Claim(s) |
Structural requirement |
| Colon cleansing preparation (aqueous) |
Claims 28 and 38 |
aqueous solution of Claim 1/31 composition |
| Sachet |
Claims 29 and 39 |
components of Claim 1/31 composition packaged as sachet |
| Kit with separated portions |
Claims 30 and 40 |
at least two portions: ascorbic acid/salts in first portion; other components in second |
What do the two independent claims (1 and 31) change in scope and how could that affect infringement?
Direct answer: Claim 1 is tighter and more explicit on sulphates being a required ingredient (1–15 g sulphate per liter) while Claim 31 shifts the PEG amount lower bound (30 g instead of 80 g) and restructures the electrolyte list so sulphates appear in the optional set (as written for Claim 31). That difference can materially affect whether a candidate product meets the literal elements.
Scope deltas to map in claim charting
-
PEG amount lower bound
- Claim 1: 80–350 g
- Claim 31: 30–350 g
A formulation with PEG at, for example, ~50–70 g may fall into Claim 31 but not Claim 1.
-
Sulphate requirement vs optionality
- Claim 1: includes alkali/alkaline earth sulphate (1–15 g) as part of required components.
- Claim 31: includes optional electrolytes list where sulphates are included among “optionally” in the provided claim text.
A formulation using electrolytes outside sulphates may avoid Claim 1 and potentially avoid Claim 31 if sulphate omission results in no sulphate inclusion meeting Claim 31 element text.
-
Both share the osmolarity window
- Both require 300–700 mOsmol/kg for reconstituted 1 liter.
How strong is the patent estate for US 7,169,381 against generic or branded colon cleansing products?
Direct answer: The estate’s strength is tied to three enforceable technical anchors: (i) reconstitution osmolarity 300–700 mOsmol/kg, (ii) inclusion of PEG + ascorbic acid system, and (iii) electrolyte selection and quantification, especially sulphates in Claim 1. Products that vary ingredient families or reconstitution osmolarity can create straightforward design-around.
Practical enforcement posture implied by claim specificity
- Ingredient ranges are relatively broad (PEG 80–350 g; ascorbic system 3–20 g; sulphate 1–15 g). This breadth can capture multiple formulations.
- Dependent claims tighten into mid-bands (PEG ≥90 to ≤150; sulphate ≥3 to ≤9; ascorbic mixture ≥5 to ≤10; osmolarity ≥330 or ≤550; PEG MW 3350/4000). These give the patentee multiple narrowing handles if the accused product matches common “sweet spot” compositions.
- Measurable boundary (osmolarity) increases evidentiary load. In litigation, the patentee must show the accused product, when made to 1 liter, falls within the claimed osmolarity. That gives a defendant a clear non-infringement lever: adjust the recipe or reconstitution procedure to land outside the range.
Key design-around levers
- Osmolarity shift: reconstituted solution outside 300–700 mOsmol/kg.
- Electrolyte substitution: remove or reduce sulphates below Claim 1’s 1–15 g requirement; avoid sulphate class if possible.
- PEG selection: choose PEG molecular weight outside ≥2000 and ≤4500 or shift outside the preferred dependent MWs; adjust PEG mass to fall outside 80–350 g (Claim 1) and/or 30–350 g (Claim 31).
- Ascorbic system alteration: omit ascorbic acid/ascorbate or move outside 3–20 g (per liter) as measured in the final admixture.
- Packaging architecture: avoid the two-portion kit structure where ascorbic system is separated into a first portion.
What patents or prior art would likely compete with this formulation envelope?
Direct answer: Within this claim theme, the closest competitive prior art typically clusters around (i) PEG-based colon cleansing compositions, (ii) electrolyte-controlled osmotic laxatives, and (iii) ascorbic acid or ascorbate-based bowel prep systems. The decisive prior art overlap for obviousness/non-infringement arguments is whether a reference teaches a composition that already meets the same PEG + ascorbic + electrolyte + osmolarity combination, particularly with sulphate inclusion and the specified PEG molecular weight constraints.
(No additional patent identifiers for the “patent landscape” can be provided from the information provided in the prompt alone, since patent numbers, filing dates, assignees, and citing documents are required for a complete map.)
What would an infringement claim chart need to prove for US 7,169,381?
Direct answer: A successful infringement case must establish each claim element against the accused product, including reconstitution conditions.
For Claim 1 (most likely asserted)
- A dry composition for admixture with water
- The composition includes, per liter of final aqueous solution:
- PEG 80–350 g
- ascorbic acid + one or more ascorbic acid salts: 3–20 g
- alkali/alkaline earth sulphate(s): 1–15 g
- optional NaCl/KCl/NaHCO₃
- The resulting aqueous solution osmolarity is 300–700 mOsmol/kg
- Dependent claims add further factual proof if asserted (PEG MW, narrower loadings, specific salts/sweeteners, coated components, kit partitioning).
For Claims 28–30 (product-form coverage)
- Show the accused colon cleansing preparation is an aqueous solution of the Claim 1 composition, or packaged as a sachet, or supplied as a kit with the specified portion separation.
For Claim 31 (alternative independent claim)
- Repeat the above but reflect:
- PEG lower bound 30 g (if asserted)
- electrolyte list structure as written (sulphates appearing among “optionally” items in the provided Claim 31 text)
When does US 7,169,381 lose exclusivity, and what matters for FDA timing?
Direct answer: A precise exclusivity calendar depends on the patent’s statutory basis (utility patent term under 35 USC 154, any PTA, and whether the patent is listed in the Orange Book for an NDA/ANDA). The information provided does not include the patent’s filing date, issuance date mechanics beyond the patent number, or any associated FDA listing details, so an exclusivity timeline cannot be stated with accuracy.
Which generic entry risks exist for PEG-ascorbate colon cleansing systems under US 7,169,381?
Direct answer: The main generic risk is that many colon cleansing products could be within range of:
- PEG + ascorbic acid/ascorbate
- electrolyte controlled osmolarity
- sachet/kit packaging variants
The main non-infringement risk for a challenger is matching the osmolarity and quantitative bounds. A challenger can reduce exposure by:
- adjusting the recipe to shift osmolarity outside 300–700 mOsmol/kg
- removing sulphates to miss Claim 1’s required sulphate element
- changing PEG MW or mass outside the narrower dependent bands
How does US 7,169,381 compare with typical PEG-electrolyte bowel prep formulations?
Direct answer: Relative to “standard” PEG-electrolyte bowel preps, this patent’s differentiator is the ascorbic acid/ascorbate system coupled with a defined osmolarity window and explicit sulphate-based electrolyte mass ranges. The PEG-electrolyte family alone is broad; this claim tightens by specifying:
- ascorbic acid + ascorbate weight fractions
- sulphate loading
- solution osmolarity
- PEG molecular weight constraints in dependent claims
That combination can narrow what “counts” as an infringing formulation even if the overall drug class is the same (colon cleansing).
Key Takeaways
- US 7,169,381 claims dry PEG + ascorbic acid/ascorbate colon cleansing compositions with reconstituted osmolarity 300–700 mOsmol/kg.
- Claim 1 requires alkali/alkaline earth sulphates (1–15 g per liter); Claim 31 uses a different formulation boundary on PEG amount (30–350 g) and structures sulphates as optional in the provided claim text.
- Dependent claims provide multiple tight ranges (PEG ≥90 to ≤150 g; sulphate ≥3 to ≤9 g; ascorbic mix ≥5 to ≤10 g; osmolarity ≥330 or ≤550; PEG MW 3350 or 4000).
- The most actionable infringement risk levers are measured osmolarity of the reconstituted solution and compliance with per-liter quantitative bounds.
- The most actionable design-around levers are shifting osmolarity outside the claimed range, omitting or replacing sulphates, changing PEG mass and/or molecular weight, and altering kit partitioning.
FAQs
-
What does “osmolarity within 300 to 700 mOsmol/kg” mean for measuring infringement?
It is a required property of the reconstituted 1-liter aqueous solution prepared from the dry admixture, making the assay method and reconstitution conditions central evidence.
-
Can a colon cleansing product avoid US 7,169,381 by excluding sulphates?
Under Claim 1, sulphates are a required component; excluding them is a direct path to non-infringement for Claim 1, assuming other elements still do not map.
-
Do the claims cover kits with separated packets for ascorbic acid?
Yes. Claims 30 and 40 cover kits with at least two portions where the ascorbic acid/salts are packaged separately from the other components.
-
Is PEG molecular weight a limitation only in dependent claims?
Yes. PEG MW limitations appear in dependent claims (eg ≥2000 Da; ≤4500 Da; specific 3350 or 4000), so infringement under the broadest independent claim does not require those MW limits.
-
Would changing the ascorbic acid to ascorbate ratio avoid infringement?
Potentially. While the independent claims require a mixture within 3–20 g, the specific weight-ratio limitations (like 1:9 to 9:1 or 4:6 to 6:4) are in dependent claims; avoiding those ratios can reduce risk if only narrower claims are asserted.
References (APA)
- United States Patent 7,169,381. (n.d.). United States Patent and Trademark Office.
